Jayakumar Rajadas

Prof. Dr. Jayakumar Rajadas

Biomaterials and Advanced Drug Delivery Laboratory, Stanford University, Stanford, CA, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

22 December 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
DDDominik Duscher
Dominik Duscher
ENEvgenios Neofytou
Evgenios Neofytou
VWVictor W. Wong
Victor W. Wong
ZMZeshaan Maan
Zeshaan Maan
RRRobert C. Rennert
Robert C. Rennert
GGGeoffrey C. Gurtner
Geoffrey C. Gurtner
Significance: Diabetes is the leading cause of nontraumatic amputations. There are no effective therapies to prevent diabetic ulcer formation and only modestly effective technologies to help with their healing. To enhance diabetic wound healing we designed a transdermal delivery system containing the FDA-approved small molecule deferoxamine, an iron chelator that increases defective hypoxia inducible factor-1 alpha transactivation in diabetes by preventing iron-catalyzed reactive oxygen stress. This system overcomes the challenge of delivering hydrophilic molecules through the normally impermeable stratum corneum and both prevents diabetic ulcer formation and improves the healing of existing diabetic wounds. This represents a prophylactic pharmacological agent to prevent ulcer formation that is rapidly translatable into the clinic and has the potential to ultimately transform the care and prevention of diabetic complications.

23 May 2017 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
MMM. Rezaa Mohammadi
M. Rezaa Mohammadi
ANAmirali Nojoomi
Amirali Nojoomi
MMMasoud Mozafari
Masoud Mozafari
ADArita Dubnika
Arita Dubnika
MIMohammed Inayathullah
Mohammed Inayathullah
Jayakumar RajadasJayakumar Rajadas
Jayakumar Rajadas
Nanoscale hybridization to fabricate all-in-one nanoparticles for superior targeted delivery systems.

6 February 2018 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
ALAndrew S. Lee
Andrew S. Lee
MIMohammed Inayathullah
Mohammed Inayathullah
MLMaarten A. Lijkwan
Maarten A. Lijkwan
XZXin Zhao
Xin Zhao
WSWenchao Sun
Wenchao Sun
JWJoseph C. Wu
Joseph C. Wu

1 August 2013 in Acta Biomaterialia
Verified
Journal Article
Closed access
WSWenchao Sun
Wenchao Sun
ZAZeynep Araci
Zeynep Araci
MIMohammed Inayathullah
Mohammed Inayathullah
SMSathish Manickam
Sathish Manickam
XZXuexiang Zhang
Xuexiang Zhang
MBManish J Butte
Manish J Butte

5 October 2017 in JCI Insight
Verified
Journal Article
Open access
PDF file
MHMichael S. Hu
Michael S. Hu
GWGraham G. Walmsley
Graham G. Walmsley
LBLeandra A. Barnes
Leandra A. Barnes
KWKipp Weiskopf
Kipp Weiskopf
RRRobert C. Rennert
Robert C. Rennert
Michael T. LongakerMichael T. Longaker
Michael T. Longaker
The monocyte lineage is essential to normal wound healing. Macrophage inhibition or knockout in mice results in impaired wound healing through reduced neovascularization, granulation tissue formation, and reepithelialization. Numerous studies have either depleted macrophages or reduced their activity in the context of wound healing. Here, we demonstrate that by increasing the number of macrophages or monocytes in the wound site above physiologic levels via pullulan-collagen composite dermal hydrogel scaffold delivery, the rate of wound healing can be significantly accelerated in both wild-type and diabetic mice, with no adverse effect on the quality of repair. Macrophages transplanted onto wounds differentiate into M1 and M2 phenotypes of different proportions at various time points, ultimately increasing angiogenesis. Given that monocytes can be readily isolated from peripheral blood without in vitro manipulation, these findings hold promise for translational medicine aimed at accelerating wound healing across a broad spectrum of diseases.